Last reviewed · How we verify
NCT06333132: DiabEATit
Deciphering the Role of Incretin Hormones in Weight Loss-induced Remission of Type 2 Diabetes (DIABeat)
NA trial testing Weight loss-induced Diabetes Remission in Obesity in 45 participants. Status unknown.
1 September 2025
Quick facts
| Lead sponsor | Azienda Ospedaliero, Universitaria Pisana |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 45 |
| Start date | 1 September 2024 |
| Primary completion | 1 September 2025 |
| Estimated completion | 1 February 2026 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Weight loss-induced Diabetes Remission
Conditions studied
- Obesity — all drugs for Obesity →
- Diabetes Mellitus Type 2 in Obese — all drugs for Diabetes Mellitus Type 2 in Obese →
Sponsor
Azienda Ospedaliero, Universitaria Pisana — full company profile →
Who can join
Adults 18 to 65, any sex, with Obesity or Diabetes Mellitus Type 2 in Obese. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this mechanistic study is to investigate the role of incretin hormones on weight loss-induced type 2 diabetes remission.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06333132
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Other Azienda Ospedaliero, Universitaria Pisana trials
Trials by the same sponsor.
- NCT07512453 — Study in Patients With Osteoporosis and Fragility Fractures to Estimate the Extent and Impact of Delayed Administration · not yet recruiting
- NCT07250607 — Extreme Phenotypes to Identify Susceptibility of Patients Living With Type 2 to Diabetes Related Complications · active not recruiting
- NCT07132086 — Prospective Observational Study on the Effectiveness of Daridorexant in Chronic Insomnia in a Real-World Setting · completed
- NCT06876948 — NENCA Study on Neurological Complications of Long COVID-19 in Children and Adolescents; Neurophysiological, Electroencep · NA · recruiting
- NCT06176482 — A Bidirectional MyoKinetic Implanted Interface for Natural Control of Artificial Limbs · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06333132 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Azienda Ospedaliero, Universitaria Pisana
- Last refreshed: 27 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06333132.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing